

CIF A-18.758.300 Avda. de la Innovación, n 1 Edificio BIC (Ofic. 211) P. T. de Ciencias de la Salud 18100 Armilla (Granada) **Tel: 958 750 598**

Mercado Alternativo Bursátil Plaza de la Lealtad, 1 28014 Madrid

In Granada, 17 December 2014

RELEVANT FACT OF NEURON BIO

In compliance with the provisions of the MAB circular 9/2010 on information to be provided by the companies in expansion integrated in the MAB the company, Neuron Bio, S.A. (hereinafter "NEURON BIO" or the "Company"), hereby puts in knowledge the following information.

- 1. This afternoon Neuron Bio has signed an agreement with Repsol to buy the 50% of Neol Biosolutions and at the same time, Neol signed a commercial framework agreement with Repsol. We enclose press release explaining both agreements.
- 2. Then, the shareholder's meeting from Neol Biosolutions (from which Neuron Bio is now the only shareholder) has appointed a Board of Directors formed by 4 members:
- Mr. José Manuel Arrojo Botija
- Mr. Javier Tallada García de la Fuente
- Mr. Fernando Valdivieso Amate
- Mr. Javier Velasco Álvarez

Kind regards,

Fernando Valdivieso Amate Chairman of the Board of Directors





CIF A-18.758.300 Avda. de la Innovación, n 1 Edificio BIC (Ofic. 211) P. T. de Ciencias de la Salud 18100 Armilla (Granada)

Tel: 958 750 598

Press Release

REPSOL AND NEURON BIO REACH AN AGREEMENT

- Neuron Bio acquires the 50% participation in Neol Biosolutions from Repsol Energy Ventures, thus controlling the 100% of the company.
- Repsol signs a framework agreement with Neol for the provision of biotechnology services.

Madrid, 17 December 2014

The biotechnology company Neuron Bio controls again the 100% of the shares of Neol Biosolutions, after having acquired the 50% of the shares from Repsol for Euro 4.5 million. Repsol has also signed a framework agreement with Neol that ensures the biotech company various projects in the area of energy applied microbiology. Due to this new agreement, Neol Biosolutions can extend its commercial activity to other clients and expand its industrial biotechnology activities. The agreement, signed the 17 December in Madrid, will represent a significant increase in the turnover of Neol during the financial year 2015 and opens up a new business line for the company in coming years. This activity complements existing ones in Neol Biosolutions related to the development of production technology for microbial and biopolymers oil, for which the company is negotiating agreements with international companies of the oleochemical sector. This acquisition allows the reinforcement of its commercial strategy, thus opening up the range of clients and strengthening the financial capacity of Neuron Bio.

Neol Biosolutions is devoted to the development of cutting-edge biotechnology in the world for its application in the chemical and energetic sector. To this end the company created a technological platform called Microbiotools by Neol®, on the basis of its exclusive collection of over 9,000 micro-organisms (bacteria, molds, fungi and microalgae) isolated from extreme ecosystems. Microbiotools by Neol® achieves the improvement of economic profitability and the reduction of the environmental impact of production processes by presenting biological more efficient alternatives to current chemical industrial processes. Thanks to the most advanced techniques of the industrial biotechnology and the molecular technology of the company, it is possible to achieve more quickly necessary yields that make a bioprocess financially viable, thus reducing the use of pollutants at the same time.

Neol Biosolutions was created in July 2012 as a 50:50 joint venture between Repsol and Neuron Bio. After its exit as shareholder from Neol, the company Repsol will continue to rely on





CIF A-18.758.300 Avda. de la Innovación, n 1 Edificio BIC (Ofic. 211) P. T. de Ciencias de la Salud 18100 Armilla (Granada) **Tel: 958 750 598**

the technical capacities and the human team of Neol Biosolutions in its fields of interest related to energy applied microbiology.

